Suppr超能文献

质子治疗与光子治疗对非小细胞肺癌挽救性再照射的毒性作用

Toxicity of Proton Therapy versus Photon Therapy on Salvage Re-Irradiation for Non-Small Cell Lung Cancer.

作者信息

Yang Kyungmi, Suh Yang-Gun, Shin Hyunju, Pyo Hongryull, Moon Sung Ho, Ahn Yong Chan, Oh Dongryul, Chung Eunah, Jo Kwanghyun, Noh Jae Myoung

机构信息

Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.

Proton Therapy Center, Research Institute and Hospital, National Cancer Center, Goyang 10408, Korea.

出版信息

Life (Basel). 2022 Feb 16;12(2):292. doi: 10.3390/life12020292.

Abstract

This study evaluated the toxicity associated with radiation techniques on curative re-irradiation (re-RT) in patients with thoracic recurrence of non-small cell lung cancer (NSCLC). From 2011 to 2019, we retrospectively reviewed the data of 63 patients with salvage re-RT for in-field or marginal recurrence of NSCLC at two independent institutions. Re-RT techniques using X-ray beams and proton beam therapy (PBT) were also included. Re-RT had a 2-year overall survival (OS) and local progression-free survival of 48.0% and 52.0%, respectively. Fifteen patients experienced grade 3 or higher toxicity after re-RT. The complication rates were 18.2% (4/22) and 26.8% (11/41) in PBT patients and X-ray patients, respectively. Airway or esophageal fistulas occurred in seven patients (11.1%). Fistulas or severe airway obstruction occurred in patients with tumors adjacent to the proximal bronchial tree and esophagus, who underwent hypofractionated radiotherapy (RT) or concurrent chemotherapy, and with a higher dose exposure to the esophagus. In conclusion, salvage re-RT was feasible even in patients with local recurrence within the previous RT field. PBT showed similar survival outcomes and toxicity to those of other techniques. However, thoracic re-RT should be performed carefully considering tumor location and RT regimens such as the fraction size and concurrent chemotherapy.

摘要

本研究评估了非小细胞肺癌(NSCLC)胸部复发患者接受根治性再照射(再放疗,re-RT)时辐射技术相关的毒性。2011年至2019年,我们回顾性分析了两家独立机构63例因NSCLC野内或边缘复发接受挽救性再放疗患者的数据。再放疗技术包括使用X线束和质子束治疗(PBT)。再放疗的2年总生存率(OS)和局部无进展生存率分别为48.0%和52.0%。15例患者在再放疗后出现3级或更高等级的毒性反应。PBT组和X线组的并发症发生率分别为18.2%(4/22)和26.8%(11/41)。7例患者(11.1%)发生气道或食管瘘。瘘管或严重气道梗阻发生在肿瘤邻近近端支气管树和食管、接受大分割放疗(RT)或同步化疗且食管受照剂量较高的患者中。总之,即使是先前放疗野内局部复发的患者,挽救性再放疗也是可行的。PBT与其他技术显示出相似的生存结果和毒性。然而,进行胸部再放疗时应仔细考虑肿瘤位置和放疗方案,如分割剂量和同步化疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eac2/8876714/b93b51d640b5/life-12-00292-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验